1-[(R)-3-(3-fluoro-5-nitro-phenoxy)-piperidin-1-yl]-ethanone | 732245-91-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[(R)-3-(3-fluoro-5-nitro-phenoxy)-piperidin-1-yl]-ethanone
• 英文别名: 1-[(3R)-3-(3-Fluoro-5-nitrophenoxy)piperidin-1-yl]ethan-1-one；1-[(3R)-3-(3-fluoro-5-nitrophenoxy)piperidin-1-yl]ethanone
• CAS: 732245-91-9
• 化学式: C₁₃H₁₅FN₂O₄
• 分子量: 282.272
• InChiKey: IDCNMRGSXNYGBE-GFCCVEGCSA-N

物化性质

• 沸点：
  449.7±45.0 °C(Predicted)
• 密度：
  1.317±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  75.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-[(R)-3-(3-fluoro-5-nitro-phenoxy)-piperidin-1-yl]-ethanone 在 N,N-二异丙基乙胺 作用下， 生成 (R)-1-[3-(1-acetyl-piperidin-3-yloxy)-5-fluoro-phenyl]-3-pyridin-3-yl-urea
  参考文献：
  名称：

  Discovery of Omecamtiv Mecarbil the First, Selective, Small Molecule Activator of Cardiac Myosin

  摘要：

  We report the design, synthesis, and optimization of the first, selective activators of cardiac myosin. Starting with a poorly soluble, nitroaromatic hit compound (1), potent, selective, and soluble myosin activators were designed culminating in the discovery of omecamtiv mecarbil (24). Compound 24 is currently in clinical trials for the treatment of systolic heart failure.

  DOI：

  10.1021/ml100138q
• 作为产物：
  描述：

  1-[(3R)-3-羟基-1-哌啶基]乙酮 、 3,5-二氟硝基苯 以 N,N-二甲基甲酰胺 为溶剂， 生成 1-[(R)-3-(3-fluoro-5-nitro-phenoxy)-piperidin-1-yl]-ethanone
  参考文献：
  名称：

  Discovery of Omecamtiv Mecarbil the First, Selective, Small Molecule Activator of Cardiac Myosin

  摘要：

  We report the design, synthesis, and optimization of the first, selective activators of cardiac myosin. Starting with a poorly soluble, nitroaromatic hit compound (1), potent, selective, and soluble myosin activators were designed culminating in the discovery of omecamtiv mecarbil (24). Compound 24 is currently in clinical trials for the treatment of systolic heart failure.

  DOI：

  10.1021/ml100138q

文献信息

• Syntheses of ureas
  申请人：Morgan Paul Bradley

  公开号：US20060025470A1

  公开（公告）日：2006-02-02

  The present invention provides intermediates, synthetic methods and novel urea compositions of matter.

  本发明提供了中间体、合成方法和新型脲类物质组合。
• Compounds, compositions and methods
  申请人：Morgan Paul Bradley

  公开号：US20050159416A1

  公开（公告）日：2005-07-21

  Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

  某些取代脲衍生物可以选择性地调节心脏肌肉纤维，例如通过增强心脏肌球蛋白，因此在治疗收缩性心力衰竭，包括充血性心力衰竭方面具有用处。
• Compounds, Compositions and Methods
  申请人：Morgan Bradley Paul

  公开号：US20090176307A1

  公开（公告）日：2009-07-09

  Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

  某些取代脲衍生物可以选择性地调节心脏肌肉节段，例如通过增强心肌肌球蛋白，因此可用于治疗收缩性心力衰竭，包括充血性心力衰竭。
• Compounds, compositions and methods of treatment for heart failure
  申请人：Cytokinetics, Inc.

  公开号：EP2397462A2

  公开（公告）日：2011-12-21

  Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

  某些取代的脲衍生物可选择性地调节心肌肌节，例如通过增强心肌肌球蛋白的作用，可用于治疗收缩性心力衰竭，包括充血性心力衰竭。
• US7176222B2
  申请人：——

  公开号：US7176222B2

  公开（公告）日：2007-02-13